Adherium Limited announced that Rick Legleiter has tendered his resignation as chief executive officer, and has provided six months' notice to enable a smooth transition to new leadership. Mr. Legleiter joined the business in May 2021 during the height of the COVID-19 pandemic. Since that time, he has led successful regulatory filings, next generation product launches and a focus on a go-to-market strategy leading to multiple agreements with major US commercial partners.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.018 AUD | -5.26% |
|
+12.50% | -67.86% |
05-24 | Adherium Partners with AstraZeneca for Hailie Smartinhaler Trial | MT |
05-23 | Adherium Raises Nearly AU$7 Million from Entitlement Offer | MT |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-67.86% | 9.25M | |
+7.23% | 217B | |
+11.31% | 191B | |
+28.94% | 154B | |
+32.00% | 112B | |
+0.15% | 62.75B | |
+16.09% | 53.34B | |
+0.94% | 48.88B | |
-2.97% | 39.36B | |
+1.23% | 35.73B |
- Stock Market
- Equities
- ADR Stock
- News Adherium Limited
- Adherium Limited Announces Resignation of Rick Legleiter as Chief Executive Officer